New Jardiance Indication? Bariatric Surgery for NASH; ICER Reviews Tirzepatide

The FDA accepted a supplemental new drug application for empagliflozin (Jardiance) as a treatment for heart failure independent of left ventricular ejection fraction in patients with or without diabetes based on the phase III EMPEROR-Preserved trial, Boehringer Ingelheim and Eli Lilly announced.

Bariatric surgery — either Roux-en-Y gastric bypass or sleeve gastrectomy — was associated with a significantly lower risk of major adverse liver and cardiovascular events in patients with nonalcoholic steatohepatitis (NASH) and obesity. (JAMA)

Intuity Medical announced that its POGO automatic blood glucose monitoring system with 10-test cartridge technology is now available in the U.S.

The FDA granted fast track designation to ALLN-346, an investigational oral treatment of hyperuricemia in patients with gout and advanced chronic kidney disease, Allena Pharmaceuticals announced.

The Institute for Clinical and Economic Review (ICER) released a new draft evidence report comparing the effectiveness and value of the investigational dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes.

Dexamethasone reduced the risk of COVID-related death and ICU admission, even in patients with diabetes. However, it increased the risk of glycemic complications by over 22 times. “We now feel confident using dexamethasone for patients with diabetes in the future, just with the caveat that it may result in a short-term worsening of their condition,” said study author Victoria Salem, MBBS, PhD, of Imperial College Healthcare NHS Trust in London. (Metabolism, Obesity and Diabetes)

The Endocrine Society announced a new Excellence in Clinical Endocrinology Leadership (ExCEL) program aimed at providing training to minority early career physicians.

Questions have been raised over payments to Donna Ryan, MD, associate editor-in-chief of Obesity, from companies that sold or were developing prescription weight-loss treatments. (STAT+, subscription required)

Please enable JavaScript to view the comments powered by Disqus.